Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8422595 | 0.82 | PTGS1 (0.49) | ALDH1A1TDP1TP53CYP3A4TSHR | |
| SCHEMBL8422593 | 0.82 | PTGS1 (0.49) | ALDH1A1TDP1TP53CYP3A4TSHR | |
| SCHEMBL19662105 | 0.80 | TUBB1 (0.38) | CYP3A4NOS2PTGS1PTGS2ALOX5 | |
| SCHEMBL14173720 | 0.78 | PTGS1 (0.53) | CYP3A4PTGS1PTGS2ALOX5EGFR | |
| SCHEMBL28450126 | 0.77 | NOS2 (0.34) | ALDH1A1TDP1CYP3A4TSHRNOS2 | |
| SCHEMBL12715623 | 0.77 | GABRA1 (0.45) | ALDH1A1TDP1TP53CYP3A4TSHR | |
| SCHEMBL12715617 | 0.77 | GABRA1 (0.45) | ALDH1A1TDP1TP53CYP3A4TSHR | |
| SCHEMBL8420391 | 0.74 | CYP3A4 (0.55) | ALDH1A1TDP1TP53CYP3A4TSHR | |
| SCHEMBL8420392 | 0.74 | CYP3A4 (0.55) | ALDH1A1TDP1TP53CYP3A4TSHR | |
| SCHEMBL14992855 | 0.71 | NOS2 (0.36) | ALDH1A1TDP1TP53CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481546-B2 | CGRP receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120059017-A1 | CGRP Receptor Antagonist | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059017-A1 | CGRP Receptor Antagonist | CALCRL, PTGIR, CALCR | ALDH1A1 1718/4885TDP1 2671/4885TP53 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.